- Benign Prostatic Hyperplasia
- Hormone Therapy
- Genomic Testing
- Next-Generation Imaging
- UTUC
- OAB and Incontinence
- Genitourinary Cancers
- Kidney Cancer
- Men's Health
- Pediatrics
- Female Urology
- Sexual Dysfunction
- Kidney Stones
- Urologic Surgery
- Bladder Cancer
- Benign Conditions
- Prostate Cancer
Dr. Murphy on legislative recommendations for PSA screening
"There's a potential for a more nuanced approach to screening where you assess baseline at 40 for all races, so that you can then determine who needs to be screened regularly or not," says Adam Murphy, MD, MBA, MSCI.
In this video, Adam Murphy, MD, MBA, MSCI, discusses potential legislative directions for PSA screening recommendations moving forward from the 2023 AUA Summit, where he was part of the discussion "Breaking Down Barriers to PSA Screening". Murphy represented R. Frank Jones Urological Society at the Summit, and he is currently an assitant professor of urology at Northwestern University's Feinberg School of Medicine in Chicago, Illinois.
Video Transcript:
The data behind Black men and men with a family history of prostate cancer is clear that they have increased risk between the ages 40 and 54. That, coupled with the fact that Black men have twice the mortality rate, even at low-risk disease, means that earlier disease detection is really important for Black men and men with family history too. There are arguments to be made where getting a baseline PSA tests at age 40, and figuring out if the patient is above or below median for their age group can also detect 90% of the men who would die of prostate cancer.
Having access to PSA screening at least a couple of times in the 40 to 54 age range would be helpful for all men. There's a potential for a more nuanced approach to screening where you assess baseline at 40 for all races, so that you can then determine who needs to be screened regularly or not. The way that it currently defines high-risk is just Black and men with family history. Expanding that to people who are above median for their PSA for their age range would be helpful for future legislation.
This transcription has been edited for clarity.
Cell-cycle risk score is predictive of ADT benefit in prostate cancer
May 17th 2024"Prolaris precisely describes the difference in metastasis outcomes for men receiving monotherapy (RT) vs multimodal therapy (RT+ADT), and further tells me precisely what the risk of death is for a man on surveillance," says Jonathan D. Tward, MD, PhD.
